Stock Ratios
Making an investment decision in the stock market involves a certain amount of risk, so it's important to thoroughly review a company's stock before making any decisions. Stock float, number of short positions and outstanding shares are among the many factors an investor should take into account.
profit margin TTM
-314.78%
operating margin TTM
-329.46%
revenue TTM
15.42 Million
revenue per share TTM
0.37$
valuation ratios | |
|---|---|
| pe ratio | -0.21 |
| peg ratio | -0.02 |
| price to book ratio | -1.23 |
| price to sales ratio | 0.68 |
| enterprise value multiple | -0.58 |
| price fair value | -1.23 |
profitability ratios | |
|---|---|
| gross profit margin | 80.11% |
| operating profit margin | -329.46% |
| pretax profit margin | -315.75% |
| net profit margin | -314.78% |
| return on assets | -151.7% |
| return on equity | -957.2% |
| return on capital employed | -211.98% |
liquidity ratio | |
|---|---|
| current ratio | 3.23 |
| quick ratio | 3.23 |
| cash ratio | 2.55 |
efficiency ratio | |
|---|---|
| days of inventory outstanding | 0.00 |
| operating cycle | 0.00 |
| days of payables outstanding | 156.43 |
| cash conversion cycle | -156.43 |
| receivables turnover | 0.00 |
| payables turnover | 2.33 |
| inventory turnover | 0.00 |
debt and solvency ratios | |
|---|---|
| debt ratio | 0.08 |
| debt equity ratio | -0.30 |
| long term debt to capitalization | 0.00 |
| total debt to capitalization | -0.42 |
| interest coverage | -50.17 |
| cash flow to debt ratio | -20.44 |
cash flow ratios | |
|---|---|
| free cash flow per share | -1.65 |
| cash per share | 0.65 |
| operating cash flow per share | -1.63 |
| free cash flow operating cash flow ratio | 1.01 |
| cash flow coverage ratios | -20.44 |
| short term coverage ratios | 0.00 |
| capital expenditure coverage ratio | -100.90 |
Frequently Asked Questions
When was the last time Carisma Therapeutics, Inc. (NASDAQ:CARM) reported earnings?
Carisma Therapeutics, Inc. (CARM) published its most recent earnings results on 07-11-2024.
What is Carisma Therapeutics, Inc.'s current ROE?
An investor's main concern is the profitability ratios of a company so that they are able to understand how it performs financially. Investors are interested in finding out how effectively a business is using their cash to produce earnings, which is why return on equity (ROE) ratio is important. Carisma Therapeutics, Inc. (NASDAQ:CARM)'s trailing twelve months ROE is -957.2%.
What are ROA telling us?
The Return on Assets (ROA) ratio measures how profitable a company is relative to its total assets. Carisma Therapeutics, Inc. (CARM) currently has a ROA of -151.7%. Companies that manage their assets effectively will have greater returns, while those that do so poorly would suffer lower returns.
Where did CARM's net profit margin stand at?
CARM reported a profit margin of -314.78% in the last quarter. A company's profit margin, also known as its revenue ratio or gross profit ratio, reflects the amount of revenue that an organization earns compared to its net income. In general, a higher ratio implies greater profit, and vice versa.
What is CARM's short-term liquidity position?
Apple's current ratio, which measures its ability to pay short-term obligations, was 3.23 in the most recent quarter. The quick ratio stood at 3.23, with a Debt/Eq ratio of -0.30.